Protocol design for high relaxivity contrast agents in MR imaging of the CNS

European Radiology, Supplement

Volumn 16, Issue 7, 2006, Pages

  Essig, Marco ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Central nervous system (CNS); Contrast agents; MRI; MultiHance

Indexed keywords

ALBUMIN; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; PROTON;

ALBUMIN BLOOD LEVEL; BRAIN DISEASE; CANCER DIAGNOSIS; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL PROTOCOL; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; HUMAN; MAGNETIC FIELD; MAGNETIC RESONANCE ANGIOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVIEW;

CENTRAL NERVOUS SYSTEM NEOPLASMS; CEREBROVASCULAR CIRCULATION; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; HUMANS; MAGNETIC RESONANCE IMAGING; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; RESEARCH DESIGN;

EID: 33845420078     PISSN: 16133749     EISSN: 16133757     Source Type: Journal    
DOI: 10.1007/s10406-006-0190-5     Document Type: Review

References (38)

1. Brant-Zawadski M, Norman D, Newton TH (1984) Magnetic resonance imaging of the brain: The optimal screening technique. Radiology 152:71-77
2. Muroff LR, Runge VM (1995) The use of MR contrast in neoplastic disease of the brain. Top Magn Reson Imaging 7:137-157
3. Edelmann RR, Hesselink JR, Zlatkin MB (1996) Clinical magnetic resonance imaging, 2nd edn. W.B. Saunders, Philadelphia
4. Essig M, Knopp MV, Schoenberg SO et al (1999) Contrast enhanced fast fluid-attenuated inversion-recovery (FLAIR) MR imaging in the assessment of primary glial tumors and brain metastases. Radiology 210:551-557
5. Kirchin MA, Runge VM (2003) Contrast agents for magnetic resonance imaging: Safety update. Top Magn Reson Imaging 14:426-435
6. de Haën C, Cabrini M, Akhnana L et al (1999) Gadobenate dimeglumine 0.5 M solution for injection (MultiHance): Pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 23 [Suppl 1]:161-168
7. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ (2005) Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 40:715-724
8. Pintaske J, Martirosian P, Graf H et al (2006) Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist) and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2 T, 1.5 T and 3 T. Invest Radiol 41:213-221. Erratum Invest Radiol, in press
9. Yuh WTC, Fisher DJ, Engelken JD et al (1991) MR evaluation of CNS tumors: Dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 180:485-491
10. Myhr G, Rinck PA, Børseth A (1992) Gadodiamide injection and gadopentetate dimeglumine: A doubleblind study in MR imaging of the CNS. Acta Radiol 33:405-409
11. Valk J, Algra PR, Hazenberg CJ et al (1993) A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system. Neuroradiology 35:173-177
12. Oudkerk M, Sijens PE, van Beek EJ, Kuijpers TJ (1995) Safety and efficacy of Dotarem (Gd-DOTA) versus Magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 30:75-78
13. Greco A, Parker JR, Ratcliffe CG et al (2001) Phase III, randomized, doubleblind, cross-over comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions. Australas Radiol 45:457-463
14. Akeson P, Larsson EM, Kristoffersen DT et al (1995) Brain metastases - comparison of gadodiamide injectionenhanced MR imaging at standard and high dose, contrast-enhanced CT and non-contrast-enhanced MR imaging. Acta Radiol 36:300-306
15. Yuh WTC, Engelsken JD, Muhonen MG et al (1992) Experience with high dose gadolinium MR imaging in the evaluation of brain metastases. AJNR Am J Neuroradiol 13:335-345
16. Yuh WTC, Fisher DJ, Runge VM et al (1994) Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases. AJNR Am J Neuroradiol 15:1037-1051
17. Sze G, Johnson C, Kawamura Y et al (1998) Comparison of single- and triple-dose contrast material in the MR screening of brain metastases. AJNR Am J Neuroradiol 19:821-828
18. Runge VM, Kirsch JE, Burke VJ et al (1992) High-dose gadoteridol in MR imaging of intracranial neoplasms. J Magn Reson Imaging 2:9-18
19. Runge VM, Wells JW, Nelson KL, Linville PM (1994) MR imaging detection of cerebral metastases with a single injection of high-dose gadoteridol. J Magn Reson Imaging 4:669-673
20. Yuh WTC, Tali ET, Nguyen HD et al (1995) The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. AJNR Am J Neuroradiol 16:373-380
21. Van Dijk P, Sijens PE, Schmitz PI, Oudkerk M (1997) Gd-enhanced MR imaging of brain metastases: Contrast as a function of dose and lesion size. Magn Reson Imaging 15:535-541
22. Haustein J, Laniado M, Niendorf HP et al (1993) Triple-dose versus standard-dose gadopentetate dimeglumine: A randomized study in 199 patients. Radiology 186:855-860
23. Erickson BJ, Campeau NG, Schreiner SA et al (2002) Triple-dose contrast/ magnetization transfer suppressed imaging of 'non-enhancing' brain gliomas. J Neurooncol 60:25-29
24. Peretti-Viton P, Taieb D, Viton JM (1998) Contrast-enhanced magnetisation transfer MRI in metastatic lesions of the brain. Neuroradiology 40:783-787
25. Cavagna FM, Maggioni F, Castelli PM et al (1997) Gd chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 32:780-796
26. Giesel FL, von Tengg-Kobligk H, Wilkinson ID et al (2006) Influence of human serum albumin on longitudinal and transverse relaxation rates (R1 and R2) of magnetic resonance contrast agents. Invest Radiol 41:222-228
27. Knopp MV, Runge VM, Essig M et al (2004) Primary and secondary brain tumors at MR imaging: Bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology 230:55-64
28. Colosimo C, Knopp MV, Barreau X et al (2004) A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours. Neuroradiology 46:655-665
29. Essig M, Tartaro A, Tartaglione T et al (2006) Enhancing lesions of the brain: Intra-individual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators. Acad Radiol 13:744-751
30. Maravilla KR, Maldjian JA, Schmalfuss IM et al (2006) Contrast enhancement of central nervous system lesions: Multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology 240:389-400
31. Essig M, Lodemann KP, Le-Huu M et al (2006) Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T. Invest Radiol 41:256-263
32. Rollin N, Guyotat J, Streichenberger N et al (2006) Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intraaxial brain tumors. Neuroradiology 48:150-159
33. Kanal E (2005) MR sequence customization for signal and contrast to noise ratio (SNR and CNR) optimization in contrast-enhanced MR imaging with higher relaxivity MR contrast agents (abstract 2395CE-e). Presented at the Annual Meeting of the Radiological Society of North America 2005. Abstracts p 794
34. Runge VM, Biswas J, Wintersperger BJ et al (2006) The efficacy of gadobenate dimeglumine (Gd-BOPTA) at 3 Tesla in brain magnetic resonance imaging: Comparison to 1.5 Tesla and a standard gadolinium chelate using a rat brain tumor model. Invest Radiol 41:224-248
35. Biswas J, Nelson CB, Runge VM et al (2005) Brain tumor enhancement in magnetic resonance imaging: Comparison of signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) at 1.5 versus 3 Tesla. Invest Radiol 40:792-797
36. Rinck PA, Muller RN (1999) Field strength and dose dependence of contrast enhancement by gadolinium-based MR contrast agents. Eur Radiol 9:998-1004
37. Knauth M, Wirth CR, Aras N, Sartor K (2001) Low-field interventional MRI in neurosurgery: Finding the right dose of contrast medium. Neuroradiology 43:254-258
38. Brekenfeld C, Foert E, Hundt W et al (2001) Enhancement of cerebral diseases: How much contrast agent is enough? Comparison of 0.1, 0.2 ad 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T. Invest Radiol 36:266-275